Physician profile
Alyssa A Putman
NPI 1407108624
$2,033.10
in general payments reported to CMS, 2019-2025
14 companies · $367 in 2025
The $367 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $145 · 2021: $389 · 2022: $215 · 2023: $382 · 2024: $310 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,059.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $493.80 | 2023-2025 | Infuse, Xiidra, Miebo |
| Kala Pharmaceuticals, INC. | $246.48 | 2021-2022 | |
| Johnson & Johnson Vision Care, INC. | $216.86 | 2019-2025 | Acuvue |
| Sight Sciences, INC. | $198.00 | 2021-2023 | Tearcare System |
| Alcon Vision LLC | $164.56 | 2020-2025 | Precision7, Total30, Rocklatan |
| Coopervision INC. | $134.14 | 2019-2024 | Misight Contact Lens |
| Aerie Pharmaceuticals, INC. | $125.00 | 2021 | |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Lkc Technologies, INC. | $119.36 | 2025 | |
| Genzyme Corporation | $94.77 | 2019 | |
| Shire North American Group INC | $63.44 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.65 | 2019 | |
| Amgen INC. | $16.53 | 2025 | Tepezza |
| Biotissue Holdings INC. | $14.52 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Putman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.